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ABSTRACT : Previous research focuses on in vitro study of stem cell metabolites derived from placenta for wound healing.
This study, however, is an advanced stage which focuses on testing the efficiency and efficacy of stem cell metabolites in rats
(Rattus novergicus). The tests carried out examined the blood levels with ELISA instruments and integument histology by
observing the activity of polymorph nuclear and monocyte cells in the control and treatment groups. In the control group, the
rats were injured in the anterior and posterior back skin with a 1×1 cm incision wound, (only antibiotics), while the treatment
group uses antibiotics and 4 mL injections of stem cell metabolites. Each group was repeated three times with the samples
observed for blood levels using ELISA Interleukin-4, Interleukin-10 and Tumor Necrosis Factor-α, with integument histology
at pre-injection, in days 1, 3 and 6. These were used to compare the development of inflammatory cells, polymorphonuclear and
monocytes between the control and treatment groups. Stem cell metabolites are significantly effective and efficient with the
ability to inhibit the inflammatory process in tissues in terms of examining the blood levels of rats using ELISA Interleukin-4,
Interleukin-10 and Tumor Necrosis Factor-α. Interleukin-4 and Interleukin-10 (anti-inflammatory) tend to significantly
increase the treatment group, while Tumor Necrosis Factor-α (pro-inflammation) increases the control group. Histology
results showed a decrease in the activity of polymorphonuclear and monocytes inflammatory cells in the treatment group
compared to the control, which indicated that the stem cell metabolites were able to significantly inhibit the inflammatory
process. It is concluded that stem cell metabolites derived from placenta are effective and efficient for wound healing in rats.
Clinical study is needed for further research for it to be used on humans.
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INTRODUCTION
Wound healing is a dynamic process consisting of
four continuous, overlapping and precisely programmed
phases, which includes complex interactions among cells,
growth factors and extracellular matrix molecules to
sequentially achieve hemostasis, cell proliferation,
angiogenesis, re-epithelialization and tissue remodeling
(Hu et al, 2014; Ya Hui et al, 2016). Each phase need to
occur in a regulated manner as interruptions, aberrancies
or prolongation has the tendency of delaying the  process
(Guo et al, 2010). A successful wound healing process
is followed by skin grafting from autograft, allograft and
synthetic tissue, resulting in infectious, scar, immune
rejection and rigid skin (Ya Hui et al, 2016).
Stem cells with their unique characteristics to self-
renew and differentiation are emerging as a promising
therapy for wounds where conventional treatments failed.
Preclinical trials have demonstrated that accelerated
wound healing is conducted using stem cell treatment via
topical or systemic delivery (McFarlin et al, 2006;
Badiavas et al, 2003). All subjects showed clinical
improvement in their wounds within days with decrease
in size without side effects associated with the delivery
of mesenchymal stem cells (Dash et al, 2009; Aggarwal
et al, 2005).
Stem cell metabolites secreted a variety of cytokines
such as IL-10, IL-4, EGF, GM-CSF and TGF-β to promote
dermal fibroblast proliferation, angiogenesis and collagen
deposition to achieve regeneration (Gnecchi et al, 2008).
These cytokines penetrates the skin layer to stimulate
the growth of new cells, increase nutrition, accelerate
skin metabolism, stimulate new proteins, collagen and
elastic fibers, also it induces basal cells to proliferate,
which results  in the growth of epidermal keratinocytes
(Kraich et al, 2006; Francisco-Cruz et al, 2014;
Massagué, 2012, Voehringer, 2012).
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In this study, stem cell metabolites were obtained
from human placenta which contains more hematopoietic
stem cell populations and mesenchymal precursor
compared to adult blood or bone marrow. Validation of
stem cell metabolites were conducted before use which
includes plasticity, purity and contamination. Furthermore,
cells are free of infectious diseases such as HIV, herpes,
hepatitis, BSE, gonorroe, and cancer. In addition, its
viability and phenotype levels need to be in accordance
with the target (Rantam et al, 2009).
Previous research focuses on the in vitro study of
stem cell metabolites derived from placenta for wound
healing. The characterization of stem cell metabolites in
vitro were conducted, which includes cytotoxicity,
cytokine detection and apoptosis assays. In conclusion,
stem cell metabolites are not toxic in terms of test results
with a percentage of cell viability which exceeds 50%.
Furthermore, stem cell metabolites do not cause any
systemic immune response to surrounding tissue in terms
of decreased levels of cytokine which is released,
excluding the induction apoptosis in terms of an increased
percentage of expression of Hsp70 (anti-apoptotic gene)
which decreases with p53 and caspase-3 (pro-apoptotic
gene) in the treatment samples (with metabolites)
compared to the controls (Purwati et al, 2019).
This is an advanced which focuses on the efficiency
and efficacy of stem cell metabolites in rats (Rattus
novergicus) for wound healing. The tests carried out
examined the blood levels in rats using ELISA instruments,
with antibiotics and stem cell metabolites used to observe
the activity of PMN and monocyte cells in control
samples.
METHODS
This study received ethical clearance from the
Animal Care and Use Committee (ACUC), Faculty of
Veterinary, Universitas Airlangga, Surabaya, Indonesia,
following the regulatory guidelines of the country.
Sample preparation : Sample preparation consisted
of placenta isolation, cell culture of mesenchymal stem
cells (MSCs) and validation. MSCs were derived from
human placenta tissue using aspiration and separation on
Histopaque-1.077. The harvested cells were cultured in
Dulbecco’s Modified Eagles Medium containing 1.0 g/L
glucose, with Penicillin-Streptomycin and Fungizone as
antibiotic and anti-fungi. Furthermore, MSCs validation
were performed and expressed asCD105, CD73,  CD90,
CD45, CD34, CD14 or CD11b, CD79 or CD19 and HLA-
DR surface molecules. Stem cell metabolites are a
medium used in cell culture (Purwati et al, 2019).
Animal Trial : Efficiency test of stem cell
metabolites in vivo was carried out in adult rats (Rattus
novergicus). The rats were injured in the anterior and
posterior back skin with a 1×1 cm incision wound.
Previously, the wounds were cleaned using providine
iodine and applied with gentamycin as an antibiotic in the
control group. While in the treatment group gentamycin
and 4 mL injection intra-muscular of stem cell metabolites
were applied, with each group repeated three times.The
samples were observed for blood levels using ELISA IL-
4, IL-10 and TNF-α, along with a integument histology
at pre-injection in day 1, 3 and 6 to compare the
development of inflammatory cells, which are
polymorphonuclear (PMN) and monocytes (MN)
between the control and treatment groups.
RESULTS
Blood level examination : The results of blood
levels examination in rats in the control and treatment
groups for 6 days are presented in Table 1, Figs. 1,  2 and 3.
Fig. 1 : Blood level examination chart for 6 days with ELISA IL-4.
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Integument histology : Observation and calculation
of the number of PMN and monocyte cells in the control
and treatment groups are presented in Tables 2 and 3.
DISCUSSION
Wound healing constitutes a complex process, where
different cells and molecules act in an orchestrating way.
The stem cell is a promising therapy in skin wound where
conventional treatments failed (Ya Hui Tang, 2016). The
mechanism enhances wound healing in the metabolites
secret anti-inflammatory cytokines and attenuate secretion
of the pro-inflammatory. These anti-inflammatory
properties make stem cells beneficial to wounds by
advancing it past a chronic inflammatory state into the
healing stage.
In this study, stem cell metabolites were extracted
from human placenta containing more hematopoietic stem
cell populations and mesenchymal precursor cells when
compared to adult blood or bone marrow. Stem cell
metabolites are rich in growth factors including
Interleukin-10, Interleukin-4, EGF (Epidermal Growth
Factor), GM-CSF (Granulocyte-Macrophage Colony-
Stimulating Factor) and TGF-β (Transforming Growth
Factor Beta). These growth factors tends to penetrate
the skin layer to stimulate the growth of new cells increase
nutrition, accelerate its metabolism, stimulate the
production of proteins, collagen and elastic fibers. It also
induces basal cells resulting in the growth of epidermal
keratinocytes.
Previous research focuses on in vitro study of stem
cell metabolites derived from placenta for wound healing,
with its characterization conducted using cytotoxicity,
cytokine detection and apoptosis assays. The study
concludes that stem cell metabolites are not toxic with
the cell viability percentage which exceeds 50%.
Furthermore, it does not lead to any systemic immune
response to surrounding tissues, fails to induce apoptosis
in terms of the percentage of Hsp70 expression (as anti-
apoptotic gene), p53 and caspase-3 expression (as pro-
apoptotic gene). This study is an advanced stage which
Table 2: Polymorphonuclear cells (PMN) in histology of the rat skin tissues.
Table 1 : Results of blood level examination in rats with ELISA instruments.
ELISA IL-4 ELISA IL-10 ELISA TNF-á
Standard/Sample
 OD Concentration (pg/ml) OD Concentration (pg/ml) OD Concentration (pg/ml)
Std 1 3.448 200 1.121 250 1.084 1000
Std 3 0.839 50 0.360 62.5 0.268 250
Std 5 0.258 12.5 0.157 15.6 0.104 62.5
Std 7 0.105 3.2 0.106 3.9 0.071 15.6
Pre-1 0.122 5.91 0.181 31.42 0.100 60
Pre-2 0.113 5.47 0.171 29.68 0.085 51.8
Day 1-P 0.123 5.95 0.177 30.72 0.101 60.69
Day 1-K 0.098 2.98 0.152 15.1 0.101 60.69
Day 3-P 0.107 5.18 0.170 29.51 0.091 54.68
Day 3-K 0.096 2.92 0.142 1.1 0.102 61.29
Day 6-P 0.093 2.83 0.148 14.7 0.089 53.48
Day 6-K 0.095 2.89 0.139 3.81 0.098 58.89
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focuses on the efficiency and efficacy of stem cell
metabolites in rats (Rattus novergicus) with tests
conducted by examining their blood levels in using ELISA
instruments and integument histology.
Growth factors are signaling proteins that function
as ligands to specific reseptor tyrosine kinase on target
cells. These reseptors in turn trigger intracellular
pathways to promote key processes such as cell growth,
division, differentiation and angiogenesis. In this study,
ELISA kits which consist of IL-4, IL-10 and TNF-α were
used to identify the inflammation process in cells. IL-4
and IL-10 are anti-inflammatory cytokine agents, while
TNF-á is pro-inflammatory. The results obtained, shows
that the concentration of IL-4 and IL-10 (pg/ml) tends to
increase significantly in the treatment group compared
to the control group from day 1 to 6. While different results
are shown on examination using ELISA TNF-α. The
TNF-α (pro-inflammatory) concentration tends to be high
in the control group and the graph rises to the 6th day.
This shows that metabolite stem cell products are
effective and efficiently inhibit the inflammatory process
in tissues.
After blood levels examinations, histological
observations were carried out on animal model using
microscope and the technique of providing tissue samples,
which begins with surgery, biopsy or autopsy. The tissue
is then processed with fixative to avoid damaging the
dosage with formalin (10% formaldehyde dissolved in
water) known as the most common animal tissue. The
fixed tissue sample is immersed in multilevel alcohol for
removing water (dehydration) and transferred to toluene
to extract alcohol (alcoholization). The final step is to
insert tissue samples into hot paraffins which infiltrate it
for 12 to 16 hours thereby, making it hard and easier to
cut using a microtome to produce a layer with a thickness
of 5 µm. This layer is then placed on the object’s glass
and colored (Maura et al, 2017).
The histology test was conducted to observe
Fig. 2 : Blood level examination chart for 6 days with ELISA IL-10.
Fig. 3 : Blood level examination chart for 6 days with ELISA TNF-á.
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inflammatory cell activity, which neutrophils consisting
of polymorphonuclear, leukocyte, and monocytes which
are a part of white blood cells from the granulocyte group.
Neutrophil granules are bluish red with three lobes, which
are clearly visible in each cell. PMN is related to the
body’s defense against bacterial infections and
inflammatory processes and is the first cell to be present
during an infection. Furthermore, the phagocytic
properties, which are similar to the macrophages, enables
PMN to attack the pathogens in the respiratory using
variety of toxic substances containing strong oxidizing
agents, including hydrogen peroxide, oxygen free radicals,
and hypochlorite (Viera et al, 2010). While monocytes
(mononuclear) are white blood groups that are part of
the immune system and identified by the cell nucleus
color. When inflammation occurs, monocyte migrates to
the site of infection and replaces the damaged cells, by
dividing or changing into one of these cells. PMN and
MN are important indicators to determine the level of
inflammation in tissues (Sallusto et al, 2010; Ginhoux et
al, 2014).
In this test, samples were divided into the control
group with only antibiotics and the treatment groups with
antibiotics and stem cell metabolites with a total of 14
rats. The observation time was according to the growth
of skin tissue and inflammation at pre-injection on day 1,
3 and 6. The skin tissue of the anterior and posterior
muscular parts with a 1x1 cm incision wound was taken
and made in the form of preparations and then stained
with Hematoxilin Eosin (HE). The making of histological
preparations was repeated 5 times for each group
followed by the proper analysis of the  data.
This study used a manual approach to determine the
average number of inflammatory cells. Tables 2 and 3
show the average number of PMN and MN, which tends
to decrease significantly from day 1 to 6 in the treatment
Table 3 : Monocytes cells (MN) in histology of the rat skin tissues.
group, compared to control. Cytokines in stem cell
metabolites such as IL-10, IL-4, EGF, GM-CSF and TGF-
β have respective roles to play in inhibiting the
inflammatory process. IL-10 has an essentially inhibitory
effect on the immune response, while IL-4 stimulates
the growth and development of the immune cells. EGF is
able to penetrate the skin layer to stimulate new cell
growth, increase nutrition, accelerate metabolism, to
produce new protein and elastic fibers. GM-CSF is able
to induce basal cells to proliferate resulting in the growth
of epidermal keratinocytes, while TGF-β works on
damaged tissue by removing debris from old
collagen.This reaction is automatic and results in activities
which result in fibroblasts being instructed to produce
more collagen and elastin.
CONCLUSION
In conclusion, stem cell metabolites are effective and
significantly inhibit the inflammatory process in tissues.
Experiments were carried out to the blood levels
examination in rats using ELISA IL-4, IL-10 and TNF-
α. IL-4 and IL-10 (anti-inflammatory) tend to increase
significantly in the treatment group, while TNF-α (pro-
inflammation) is higher in the control group. Histology
results showed a decrease in the activity of PMN and
MN inflammatory cells in the treatment group compared
to control, which indicated that the stem cell metabolites
were able to significantly inhibit the inflammatory process.
Clinical study is needed for further research so this product
can be used in human.
Ethics approval
This study received ethical clearance with No.
2.KE.023.02.2019 from Animal Care and Use Committee
(ACUC), Faculty of Veterinary, Universitas Airlangga,
Surabaya, Indonesia following the regulatory guidelines
of the country.
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